View Older Stories
-
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
-
EMA committee recommends approval for Moderna's flu-COVID combo vaccine
-
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influen
-
Stifel: 'We can see why QURE shares are lower on CNBC comments from FDA'
-
Moderna (MRNA) PT Raised to $69 at Piper Sandler
-
BioNTech sues Moderna for U.S. patent infringement over covid vaccine MNEXspike - Court filing
-
Moderna to Present at Upcoming Conferences in March 2026
-
FDA accepts Moderna flu vaccine application for review
-
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
-
Moderna (MRNA) PT Raised to $45 at Bernstein SocGen Group
-
Moderna (MRNA) PT Raised to $30 at RBC Capital
-
Moderna (MRNA) Tops Q4 EPS by 51c, Beats on Revenue
-
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
-
Moderna earnings preview Q4: weak print expected amid vaccine slowdown
-
Moderna (MRNA) call put ratio 1.2 calls to 1 put into quarter results
-
Moderna (MRNA) call put ratio 1.9 calls to 1 put into quarter results
-
Moderna Stock Alert: - Kehoe Law Firm, P.C. Investigating Securities Claims on Behalf of Moderna Investors - MRNA
-
Moderna (MRNA) call put ratio 4.3 calls to 1 put into headlines and quarter results
-
Moderna (MRNA) PT Lowered to $24 at BofA Securities
-
Moderna receives FDA refusal to review flu vaccine application
-
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
-
Moderna signs five-year agreement with Mexico for vaccine supply
-
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
-
Arbutus Biopharma wins patent ruling against Moderna
-
Moderna names David Berman as chief development officer
-
Dr. David Berman to Join Moderna as Chief Development Officer
-
Moderna (MRNA) PT Lowered to $17 at Leerink Partners
-
Moderna partners with Recordati for rare disease drug commercialization
-
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
-
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
-
Moderna (MRNA) curbing investment in vaccine trials due to U.S. backlash - Bloomberg
-
This U.S. biotech stock is Bernstein's Top Pick for 2026
-
Moderna (MRNA) PT Raised to $35 at Bernstein SocGen Group
-
Investing.com’s stocks of the week
-
Moderna and Merck report sustained melanoma treatment benefits at 5 years
-
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in P
-
Moderna (MRNA) call put ratio 4.4 calls to 1 put with a focus on January calls as share price up 6.8%
-
RBC Capital on Moderna (MRNA): 'we remain cautious on MRNA's ability to break even in 2028'
-
Moderna raises 2025 revenue forecast to $1.9 billion
-
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
-
Moderna (MRNA) call put ratio 1.2 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
UBS Assumes Moderna (MRNA) at Neutral
-
Moderna (MRNA) PT Raised to $24 at BofA Securities
-
Jefferies on Moderna (MRNA): '2026 Remains a Covid Story'
-
Moderna targets $1.6-2.0 billion revenue for 2025 amid product launches
-
Moderna files for approval of flu vaccine in four countries
-
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
-
Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
-
CEPI invests $54.3 million in Moderna's H5 pandemic flu vaccine trial
-
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
